peptidefix

Peptides / VIP (vasoactive intestinal peptide) / United States

VIP (vasoactive intestinal peptide) in the United States

Legal status, what it is, and the listed suppliers in the United States that list it.

Legal status in the United States

Not an approved medicine.

As understood at 2026-09-22. Verify with the FDA.

What VIP (vasoactive intestinal peptide) is

Vasoactive intestinal peptide is a 28-amino-acid hormone and neurotransmitter made in the gut, pancreas and nervous system. It widens blood vessels, relaxes smooth muscle and modulates inflammation. The synthetic form, aviptadil, is a licensed medicine in the UK in combination with phentolamine (Invicorp) for erectile dysfunction, and has been studied by inhalation and infusion for lung conditions. Unlike most peptides on this site, VIP is a natural human hormone with a long research history.

Full VIP (vasoactive intestinal peptide) page: targets and research →

Listed suppliers in the United States

3 of the 10 suppliers we list in the United States list VIP (vasoactive intestinal peptide). Listed, not endorsed: each row is the supplier’s own stated terms.

Direct Peptides United States All products are sold strictly for laboratory research use only and are not for human or animal consumption. Direct Peptides is a chemical supplier, not a compounding pharmacy or 503A/503B facility. Nationwide Peptides United States For Research Use Only. Products are not intended for human or animal consumption, ingestion, injection, or any form of administration. Protide Health United States All products are supplied for laboratory research only and are not for human or animal consumption, medical use, veterinary use, or any therapeutic, diagnostic, or clinical purpose.

Clinical Research

Inhalation of vasoactive intestinal peptide in pulmonary hypertension
Leuchte HH, Baezner C, Baumgartner RA, et al. (2008). European Respiratory Journal. human patients with pulmonary hypertension, n=20, single inhaled dose during catheterisation
The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial
Youssef JG, Lavin P, Schoenfeld DA, et al. (2022). Critical Care Medicine. human patients with COVID-19 respiratory failure, randomised placebo-controlled trial, n=196, ten US hospitals
Mechanisms of vasoactive intestinal peptide-mediated vasodilation in human skin
Wilkins BW, Chung LH, Tublitz NJ, Wong BJ, Minson CT (2004). Journal of Applied Physiology. human healthy volunteers, n=43, intradermal microdialysis
Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females
Simon RA, Barazanji N, Jones MP, et al. (2021). Scientific Reports. human healthy females, n=37, observational (plasma VIP, questionnaires, MRI)
Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease
Duffy LC, Zielezny MA, Riepenhoff-Talty M, et al. (1989). Digestive Diseases and Sciences. human adults with inflammatory bowel disease, n=115 (48 ulcerative colitis, 67 Crohn's), observational over six months